Introduction
Since nonreplicating adenoviral vectors (AdVs) have limited efficiency in the treatment of malignant tumors, the use of restricted replication-competent adenoviruses (RRCAs) developed to replicate specifically in tumor cells only has gained widespread interest. RRCAs have a replication potential that allows extensive tumor cell infection and viro-oncolysis, while the restriction of viral replication to tumors avoids damage to the normal host's tissues improving the safety of the therapy. 1 Restriction of RRCA replication to cancer cells only has been attempted either by deletion of wild-type adenoviral genes encoding cell cycle regulatory proteins, or by the employment of tissue-specific promoters to restrict the expression of viral genes essential for virus replication. 2 The first RRCA developed, designated ONYX-015, carries a mutation in the E1B region that prevents expression of a functional E1B55kDa protein and should therefore selectively replicate in and kill p53-deficient tumor cells only. 3, 4 It is now known, however, that ONYX-015 can also replicate in tumor cells with wild-type p53. [5] [6] [7] [8] Other RRCAs, named KD1, KD3, 9 SPB-KD1, 10 dl922-947,
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D24, 12 and 01/PEME, 13 contain deletions in the E1A gene that abolish the ability of E1A to deregulate the cell cycle proteins p300 and pRB, respectively, preventing progression of cells to the S phase, and a part of these RRCAs contain additional genetic modifications increasing their viro-oncolytic potential. These RRCAs replicate very well in many cancer cells, whereas their replication was poor in quiescent cell lines. Another approach to the development of RRCAs is the employment of tumor cell-specific promoters to drive E1A gene expression. It has been shown that RRCAs expressing the adenoviral E1A gene under the control of a prostatespecific enhancer/promoter 14 for the treatment of prostate cancer, from the a-fetopotein gene promoter for hepatocellular carcinomas, [15] [16] [17] from the DF3/MUC1 promoter for human breast carcinomas, 18 from the tyrosinase promoter for melanomas, 19, 20 and from the osteocalcin promoter for bone metastases, 21 could achieve tumor cell-specific cytotoxicity. A further increase in the specificity of RRCAs could be achieved by the replacement of additional adenoviral promoters, for example, in the RRCA variant CV787 where the E1A promoter was replaced by a prostate-specific rat probasin promoter and additionally the E1B promoter by a prostate-specific enhancer/promoter. 22 In other RRCAs, the E1A and E4 promoters have been replaced by a small portion of the pS2 promoter containing two estrogen-responsive elements, or by a minimal dual-specific promoter that responds to estrogen and hypoxia, both for the treatment of estrogen receptor-positive breast cancer. 23, 24 Furthermore, cytotoxicity could be modulated by antiestrogen treatment in the latter study.
Despite these encouraging preclinical and clinical data on tumor-specific adenoviral viro-oncolysis by using several RRCAs, so far no RRCA could be developed that was completely silent in primary human cells. In particular, at higher RRCA doses cytotoxicity was observed in normal human cells also. 4, 13, 20 Although in mouse tumor xenograft models, little effect of RRCAs on surrounding normal tissue was observed, 3, 15, 25 this has only limited relevance for the prediction of dissemination and replication of RRCAs after intratumoral vector administration in humans, since rodent cells are several orders of magnitude less susceptible to infection by human adenoviruses than human cells. [26] [27] [28] Furthermore, beyond the specificity issue, external control of RRCA replication and, in particular, vector blockade in case of serious side effects is impossible. Therefore, additional safety features are desirable that further minimize the potential risk for humans.
One promising approach appears to be the use of RRCAs that in addition to the tumor-specific features of conventional RRCAs carry pharmacologically regulatable promoters. This latter feature offers the way to control adenoviral replication temporally and from outside. To this end, it has been shown that adenoviral replication can be regulated via control of E1A gene expression by a mouse mammary tumor virus (MMTV) promoter through addition of dexamethasone or its antagonist RU486 29 or by use of the rapamycin dimerization system. 30 Another study found that addition of ganciclovir to an AdV expressing the herpes simplex virus thymide kinase (HSV-tk) from an E1B-deleted adenovirus inhibits adenoviral replication in vivo. 31 Here, we report on a novel, pharmacologically regulatable RRCA system based on a Tet-On gene expression system employing an enhanced second-generation reverse tetracycline (tet)-controlled transactivator (rtTA2(s)-M2) and a tet-controlled transcriptional silencer (tTS). The system enables external pharmacological control of the replication of an E1B/E3-deleted tumor-selective RRCA, but also of transgene expression of a coinfected replicationdeficient AdV, by the use of the nontoxic effector doxycycline (dox). We also delineate, based on the tTS component of the system, a new principle of 'tissue protective' cancer gene therapy employing a liver cell-specific human a1-antitrypsin (hAAT) promoter for the regulation of the tTS in vitro and in vivo.
Results
Failure of E1A regulation in the rtTA-RRCA system
In order to control the adenoviral replication, we constructed a panel of transactivator (Ad5CMVrtTA), transrepressor (Ad5CMVtTS, Ad5 hAAT tTS), and response adenovectors (AdVs) (Ad5TREluc; Ad5TRE-E1A ¼ RRCA) (Figure 1 ). The transactivator-AdV contained the second-generation reverse tet-controlled transactivator rtTA2(s)-M2, 32 which has been shown to be able to improve the control of dox-dependent AdV-mediated transgene expression 32 and to be useful for the strict control of HIV replication 33 when used as a component of the Tet-On system. In agreement with these results, we found a strong dox-dependent increase of luciferase gene expression (32-to 631-fold, dependent on cell line) when cells were coinfected with Ad5CMVrtTA and Ad5TREluc, and only minimal background activity under noninduced conditions. Furthermore, the absolute luciferase expression level was in six of the nine investigated cell lines three-to 142-fold higher than in cells transduced with a conventional AdV expressing luciferase under the control of a CMV promoter (data not shown).
Surprisingly, however, strong E1A-13S-and -12S-mRNA expression was detected in the presence and absence of dox if the Ad5TRE-E1A was used as the response AdV (the rtTA-RRCA system). Moreover, unexpectedly high basal background expression of 13S-mRNA was seen even in the absence of both Ad5CMVrtTA and dox, with levels reaching similar values as in the presence of both dox and Ad5CMVrtTA Figure 1 Regulatory and response AdVs used in this study. A schematic outline of the modifications introduced into the 5'-end of the E1-/E3-adenovirus mutant RR5 is shown. Numbers refer to nucleotide positions of the adenoviral genome. rtTA, reverse tet-controlled transactivator rtTA2(s)-M2; tTS, tet-controlled transcriptional silencer; hAAT, human a1-antitrypsin promoter (encompasses the sequence between À357 and +56 bp); TRE, tet-response element, consisting of seven copies of the tet operator; CMV min , minimal CMV promoter (encompasses the sequence between À53 and +75 bp of the human cytomegalovirus IE1 gene promoter region). Figure 2a ). We hypothesized that very low amounts of the adenoviral E1A-13S protein expressed as a result of minimal basal background activity of the CMV min promoter may -via positive feedback loop-cause 'autoactivation' of the system.
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E1A-13S transactivates the CMV min
In order to analyze in more detail the transactivating potential of the E1A gene products upon the CMV min promoter, we cotransfected EA.hy926 cells with E1A-13S-and E1A-12S-expressing plasmids and the adenoviral shuttle plasmid pAd5TRE-luc, which expresses luciferase under the control of CMV min . Only E1A-13S but not E1A-12S, a splice variant of E1A-13S-mRNA lacking the CR3 domain, was able to transactivate CMV min -driven transcription (Figure 2b) . Apparently, the key mechanism of uncontrolled E1A-13S-and -12S-mRNA expression as seen in the rtTA-RRCA system ( Figure 2 ) appears to be E1A-13S-mediated 'autoactivation' via a positive feedback loop.
Tight Control of E1A expression by use of a tTS
It has been shown previously that a tTS 34 constructed as a fusion protein consisting of the reverse tetracycline repressor (TetR) and the KRAB-AB repressor domain of the Kid-1 protein, 34, 35 or the TetR and the KRAB repressor domain of Kox-1, 36 allows a reduction of the transgene expression to a level comparable to that of untransduced cells, by inhibition of CMV min -driven gene expression in the Tet-On system 37 and is also able to suppress the E1A-13S-mediated transactivation of viral promoters. 38 The rtTA and tTS, respectively, show opposite responses to dox. 37 In order to control E1A-13S expression, we coinfected EA.hy926 cells with Ad5CMVrtTA, Ad5CMVtTS and Ad5TRE-E1A (the rtTA-tTS-RRCA system). Under these conditions, 13S-mRNA expression was efficiently inhibited in the absence of dox, while in the presence of dox strong 13S-mRNA expression occurred ( Figure 3 ).
Control of vector replication in three related dox-controlled RRCA systems
We compared the potential of three different AdV-based dox-controlled RRCA systems to regulate adenoviral DNA replication. In addition to the above-described rtTA-RRCA and rtTA-tTS-RRCA systems, we tested the EA.hy926 cells were coinfected with each 2.5 Â 10 3 p/c of Ad5CMVrtTA plus Ad5TRE-E1A (the rtTA-RRCA system), or with Ad5TRE-E1A plus Ad5CMVrTTP (for dose equivalency), respectively, for 2 h. The rtTA-RRCA system was then induced by dox. Total RNA was isolated 24 and 48 h later and E1A-13S-and -12S-mRNA expression was detected by Northern blotting. No significant differences in the expression levels of E1A-13S-and -12S-mRNA in the presence versus absence of dox were detectable, nor in comparison with Ad5TRE-E1A-transduced cells. (b) CR3 domain of E1A-13S transactivates CMV min . EA.hy926 cells were cotransfected with pTRE-E1A plus pTRE-luc, with pTRE-12S plus TRE-luc, or with pTRE-luc alone, respectively (for more details see Materials and methods). E1A-13S transactivates the TRE-controlled CMV min -driven gene expression, while E1A-12S, which is a splice variant of E1A-13S, lacking the CR3 domain of E1A-13S does not transactivate the TRE-controlled CMV min promoter. 
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AdV-tTS-RRCA system. In the latter system, adenoviral replication should theoretically occur in the presence of dox, when it is induced by 'autoactivation' of the CMV min promoter by E1A-13S, whereas replication should be inhibited by tTS in the absence of dox.
Comparison of the three systems showed that the most effective regulation was seen if the target cells were transduced with the rtTA-tTS-RRCA system ( Figure 4a ). The amount of newly synthesized adenoviral DNA was around seven-fold higher under induced as compared to uninduced conditions and consequently three-fold higher than in the rtTA-RRCA and the tTS-RRCA systems.
The tTS-RRCA system showed inhibition of AdV DNA replication in the absence of dox, similar to the rtTA-tTS-RRCA system, but the absolute amount of newly synthesized AdV genome reached only 22% (use of 20 p/c of Ad5TRE-E1A) to 75% (2.5 Â 10 3 p/c Ad5TRE-E1A) of the rtTA-tTS-RRCA system. The rtTA-RRCA system showed the strongest adenoviral DNA replication in the presence of dox, while in the absence of dox, adenoviral DNA replication was 1.1-fold (20 p/c of Ad5TRE-E1A) to 2.2-fold (2.5 Â 10 3 p/c Ad5TRE-E1A) higher as compared to the AdV-rtTA-tTS-RRCA system under induced conditions. These results confirm the proposed mechanisms of regulation of E1A-13S expression discussed above and their application for the control 3 p/c of Ad5CMVrtTA or Ad5CMVrTTP (to achieve equivalent total AdV doses), respectively. After 24 h, later 5 Â 10 2 p/c of Ad5TREluc plus different amounts of Ad5TRE-E1A were added for 2 h. Ad5CMVrTTP was again added for dose equivalency. The cell culture medium was replaced and E1A-13S expression was induced by dox. Adenoviral DNA replication was measured 48 h later. The quantities of luciferase DNA measured were normalized against the luciferase DNA content of cells cotransduced with Ad5CMVluc only and 'filled-on' with Ad5CMVrTTP (set¼1). (b) Postulated regulatory mechanisms in the rtTA-tTS-RRCA, rtTA-RRCA, and tTS-RRCA systems. (I) rtTA-tTS-RRCA system: In the presence of dox, rtTA2(s)-M2 binds to the TRE and activates CMV min -driven E1A-13S expression which results in efficient vector replication. E1A-13S also transactivates CMV min via an 'autoactivation' positive feedback loop. The tTS is unable to bind to the TRE. In the absence of dox, the tTS binds to the TRE and inhibits background expression of the CMV min . The rtTA2(s)-M2 does not bind to the TRE. Note: tTS is also able to inhibit strongly E1A-13S transactivation of the CMV min . Therefore, both the reduction of the minimal background activation of CMV min and the inhibition of the E1A-13S 'autoactivation' positive feedback loop result in strong inhibition of non specific adenoviral replication in the absence of dox. The rtTA-tTS-RRCA system therefore results in tight dox-dependent regulation of adenoviral replication. (II) rtTA-RRCA system: In the presence of dox, the mechanism of adenoviral replication is similar as described in (I) for the rtTA-tTS-RRCA system. In the absence of dox, E1A-13S is expressed from the CMV min because of the minimal basal background activity of the CMV min and its transactivation by the 'autoactivation' positive feedback loop which finally results in strong adenoviral replication. Since E1A-13S expression occurs with and without dox, this system is inefficient to achieve dox-dependent regulation of adenoviral replication. (III) tTS-RRCA system: In the presence of dox, E1A-13S is expressed from the CMV min because of background activity of the CMV min and its 'autoactivation' as described in (II). The tTS does not bind to the TRE. In the absence of dox, the tTS binds to the TRE and inhibits background expression of the CMV min and its E1A-13S-mediated 'autoactivation'. This system has similar background activity as the rtTA-tTA-RRCA system; however, the maximum level of adenoviral replication achievable with this system appears to be lower. (Figure 4b) . The results on adenoviral DNA replication were further confirmed at a functional level by cell killing assays in EA.hy926 and MeWo cells. The rtTA-tTS-RRCA and tTS-RRCA systems were the most tightly controllable systems. Both systems enabled efficient disruption of the target cells in the presence of dox, in a similar manner as replication competent adenovirus (RCA), while in the absence of dox the cells were protected. In strong contrast, the rtTA-RRCA system led to strong cytolysis of cells even in the absence of dox ( Figure 5 ).
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Modulation of transgene expression of coinfected replication-deficient vectors by the dox-controlled RRCA systems
Combination therapy employing RRCAs plus AdVs expressing cytotoxic proteins at high levels appears to enhance the antitumor efficacy. 23, 25 In order to determine whether coinfection with any of the three RRCA systems enables high and regulatable luciferase expression from a replication-deficient AdV, Ad5TREluc was coinfected with any of the three RRCA systems in HT-29 and HepG2 tumor cells. Only the rtTA-tTS-RRCA system enabled both tightly controllable and high expression of luciferase. Application of dox results in a 488-and 301-fold increase of luciferase expression in HT-29 and HepG2 cells, respectively, as compared to the uninduced system. In contrast, the rtTA-RRCA system showed a higher luciferase expression than the rtTA-tTS-RRCA system after the addition of dox, but the background activity in the uninduced system was very high and the luciferase expression therefore increased only 38-and 12-fold, respectively. The tTS-RRCA system showed only a very low peak luciferase expression when the system was induced by dox, while the background activity was comparable to that found for the rtTA-tTS-RRCA system. This resulted in only weak inducibility of the system in the presence of dox by a factor of 14-and 12-fold, respectively ( Figure 6 ).
On-off switch of the rtTA-tTS-RRCA system
The safety concept for cancer gene therapy employing the dox-controlled RRCA system also includes the switching off of adenoviral replication. For this reason, we either infected HT-29 cells with the rtTA-tTS-RRCA system and induced adenoviral replication permanently by daily addition of dox over a period of 4 days, or we infected cells with the rtTA-tTS-RRCA system and induced it with dox only transiently for 1 day. We found a strong decrease by 63% of newly synthesized adenoviral DNA in the transiently induced rtTA-tTS-RRCA system after the removal of dox, as compared to the permanently induced system (Figure 7) , which confirms the on-off safety feature of the system. E1B-deleted RRCA replicates in primary human cells but may be controlled by the rtTA-tTS-RRCA system Primary human keratinocytes and fibroblasts have been reported to be highly resistant to E1B-deleted adeno- Figure 5 Cytotoxic potential and quality of external control of the rtTAtTS-RRCA, rtTA-RRCA, and tTS-RRCA systems. EA.hy926 cells or MeWo cells were infected as described in Materials and methods for the cell killing assay. CPE was monitored by staining viable cells with crystal violet 6 days (EA.hy926) or 4 days (MeWo) after infection of the cells, respectively. Figure 6 Influence of the rtTA-tTS-RRCA (1), rtTA-RRCA (2), and tTS-RRCA (3) systems upon the transgene expression level of a cotransduced replication-deficient AdV. Depending on the respective system, cells were transduced as described in Figure 5 . Luciferase activity was measured 48 h later. , and 5 Â 10 3 p/c of Ad5TRE-E1A, respectively. However, 8 days after infection, cell viability was strongly reduced. As compared to cells transduced with a replication-deficient GFP-expressing AdV, only 43, 11, and 2% of cells, respectively, were still viable. Therefore, in order to investigate the replication rate of the Ad5TRE-E1A in normal human cells and to test whether adenoviral replication may be significantly inhibited by the dox-dependent RRCA system, we infected primary human dermal fibroblasts with the tightly regulatable rtTA-tTS-RRCA system. Adenoviral DNA replication in the presence of dox was detected at rather high Ad5TRE-E1A doses Z5 Â 10 2 p/c. The amount of newly synthesized adenoviral DNA increased up to 40-fold at the highest Ad5TRE-E1A dose used (2.5 Â 10 3 p/c). However, when compared to HT-29 tumor cells adenoviral replication in primary human fibroblasts in the presence of dox reached only 10% (use of 20 p/c Ad5TRE-E1A) to 30% (2.5 Â 10 3 p/c Ad5TRE-E1A) of the level in HT-29 cells. Under uninduced conditions, Ad5TRE-E1A-mediated adenoviral DNA replication increased only seven-fold at the highest used Ad5TRE-E1A dose of 2.5 Â 10 3 p/c (Figure 8 ). The results indicate that E1B-deleted RRCA replicate at a lower rate in primary human cells than in human tumor cells, but that at higher doses, nevertheless, significant replication and damage to the primary human cells occurs. The data also show that the rtTA-tTS-RRCA system enables control of adenoviral replication in these cells even at very high RRCA doses.
Ad5 hAAT tTS protects cells with hAAT promoter activity from RRCA-mediated viro-oncolysis in vivo
To further develop the rtTA-tTS-RRCA system, we constructed an AdV that expresses the tTS (Ad5 hAAT tTS) under the control of a strong liver cell-specific hAAT promoter, 40 in order to test the principle whether a particular tissue can be specifically 'protected' from RRCA replication. This may be useful for the treatment of liver metastases when normal hepatocytes surrounding the metastases should be protected against RRCA replication and cell killing. Different cell lines with (HepG2) or without (EA.hy926) endogenous hAAT promoter activity were infected, respectively, with the rtTA-tTS-RRCA or with the rtTA-hAAT tTS-RRCA system. The hAAT promoter-mediated tTS expression was strong enough to efficiently inhibit RRCA-mediated cell lysis in the absence of dox in HepG2 cells, whereas EA.hy926 cells were not protected against viro-oncolysis (Figure 9a ). This indicates that the hAAT promoterdriven tissue-specific expression of the tTS was sufficient to inhibit RRCA replication. Moreover, HepG2 cells could be protected against viro-oncolysis by the use of the Ad5 hAAT tTS in a similar manner as previously done for the Ad5CMVtTS. To test the new principle of 'tissue protective' gene therapy in vivo, we subcutaneously injected HepG2 cells preinfected with the rtTA-hAAT tTS-RRCA system into nude mice and analyzed the resulting tumor growth in the absence versus the presence of dox 9 weeks later. If animals injected with cells pretreated with the rtTA-hAAT tTS-RRCA system and receiving dox over the whole investigation period were compared to animals injected with tumor cells pretreated with replication-deficient control AdVs, the tumor volume in the first group was significantly reduced by 53%. If the animals injected with tumor cells pretreated with the rtTA-hAAT tTS-RRCA system and receiving dox were compared to animals injected with identically Control of adenovirus replication in primary human dermal fibroblasts with the rtTA-tTS-RRCA System. Cells were infected with the rtTA-tTS-RRCA system as described in Figure 4 . E1B-deleted Ad5TRE-E1A was able to replicate in primary human dermal fibroblasts, although with lower efficiency than in HT-29 tumor cells (Figure 4) . De novo synthesis of adenoviral DNA was strongly reduced in the absence of dox.
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pretreated cells but not receiving dox, the tumor volume was also significantly reduced by 39% in the first group (Figure 9b) . These results indicate that by using the rtTA-hAAT tTS-RRCA system, tumor cells can be destructed both in vitro and in vivo, that adenoviral replication can be controlled by dox, and that tissuespecific expression of the tTS is sufficient to inhibit Ad5TRE-E1A replication in the absence of dox.
Discussion
The use of RRCAs for tumor gene therapy has gained widespread interest since RRCAs have the potential to overcome certain limitations of conventional replicationdeficient AdVs by their capacity to disseminate its progeny within the neoplastic tissue. This results in infection and lysis of far more tumor cells as compared to conventional vectors. In several aminal models 9, 10, 25, 41 and in phase I and II clinical gene therapy trials in humans, it has been shown that RRCA were generally rather well tolerated. 3, [42] [43] [44] [45] However, RRCAs induces viremia, thereby strong immune responses, and individually variable toxic side effects. 43 The death of a patient on an adenoviral gene therapy protocol involving the use of a replication-deficient AdV 46 emphasizes the need to develop RRCA with the highest possible safety standards. One of the imperfections of most currently investigated RRCAs is the lack of features allowing control of their replication from the outside, so that after its injection external control or inhibition of virus replication is impossible.
To achieve external control of RRCA replication, we inserted elements of the Tet-On gene regulatory system in several AdVs (Figure 1 ), aiming to control adenoviral replication via regulated E1A gene expression. While in accordance with former investigations, 32 we found that the use of the new second-generation rtTA2(s)-M2 in the AdV-based Tet-On system enables high level and strictly dox-controlled expression of a reporter transgene from a replication-deficient AdV, E1A gene expression could not be regulated by dox in this rtTA-RRCA system. E1A-13S acts as transactivator of adenoviral promoters and can transactivate the CMV promoter. 47, 48 Our results demonstrate that minimal E1A-13S expression, which resulted from the minimal background activity of the CMV min in the uninduced system, was sufficient to induce an autoactivation positive feedback loop and results in uncontrollable E1A-13S expression. 49 To inhibit this unwanted endogenous feedback loop and to restore proper activation by dox only a second regulatory AdV (the Ad5CMVtTS) expressing the doxcontrolled transcriptional silencer (tTS) 34 was developed. We found that addition of the Ad5CMVtTS to the rtTA-RRCA system (yielding the rtTA-tTS-RRCA system) resulted in efficient suppression of 13S-mRNA expression in the absence of dox, whereas strong 13S-mRNA expression was maintained under induced conditions. Both reduction of the basal activity of the CMV min promoter and inhibition of the 'autoinduction' by E1A-13S were involved in this process: the main mechanism is reduction of E1A-13S-mediated transactivation of the CMV min (data not shown).
Based on different combinations of the regulatory AdVs Ad5CMVtTS and Ad5CMVrtTA, and the response RRCA Ad5TRE-E1A, we evaluated three related doxcontrolled RRCA systems with respect to their ability to regulate adenoviral DNA replication and tumor cell killing in a dox-dependent manner. The rtTA-tTS-RRCA system best fulfilled this purpose, with around sevenfold higher adenoviral replication in presence as compared to in absence of dox. As a functional consequence, In vivo subcutaneous tumor xenograft. HepG2 cells preinfected with the rtTA-hAAT tTS-RRCA system were injected subcutaneously into nude mice and analyzed for tumor growth in the absence versus presence of dox 9 weeks later. Tumor growth was significantly reduced in animals injected with cells pretreated with the rtTA-hAAT tTS-RRCA system and receiving dox, as compared to animals also injected with cells pretreated with the rtTA-hAAT tTS-RRCA system but not receiving dox. No significant differences in tumor growth were observed between controls and animals injected with cells pretreated with the rtTA-hAAT tTS-RRCA system but not receiving dox.
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cells infected with the rtTA-tTS-RRCA system were protected against viro-oncolysis in the presence of dox whereas they were lysed in its absence. Another system, the tTS-RRCA in which E1A-13S expression is triggered even in the absence of dox by activation of CMV min through E1A-13S, yielded at higher doses of Ad5TRE-E1A a similar virooncolytic efficiency as the rtTA-tTS-RRCA system emphasizing the key importance of the E1A-13S-mediated 'autoactivation' loop. The rtTA-RRCA system did not fulfill the requirements with regard to safety and regulatability when high RRCA doses were used. Interestingly, the rtTA-tTS-RRCA and tTS-RRCA systems showed similar cytotoxicity in the presence of dox as a conventional RCA ( Figure 5 ). Several studies have found increased tumor toxicity when an RRCA was combined with a conventional replication-deficient AdV expressing tumor-toxic transgenes such as IL-2 or HSV-tk. 25, 50, 51 Such systems require strong RRCA replication for efficient spreading of the AdV among the tumor cells, and strong expression of the toxic transgene to reach maximal therapeutic efficiency. Among the three tested dox-controlled RRCA systems, only the rtTA-tTS-RRCA system fulfilled this requirement. It enabled both strictly dox-controlled and highlevel expression of transgenes from a replication-deficient AdV, and tightly regulatable adenoviral replication (Figures 5 and 6 ). It also fulfilled another important requirement for a regulated system, the ability to be switched on and off. De novo synthesis of adenoviral DNA was reduced by more than 60% in the transiently induced system shortly after switching off the system (Figure 7 ). This should allow to inhibit spreading of the RRCA after termination of therapy, or during therapy if serious side effects occur.
RRCA should selectively replicate in tumor cells only and efficiently destroy them, whereas it should be strongly attenuated in normal human cells. However, when primary human cells were infected with high doses of RRCA, significant toxicity and cell killing was observed. 4 In accordance with these observations, we observed that the E1B-deleted Ad5TRE-E1A was able to replicate and kill primary human cells. In human tumor gene therapy, high doses and repeated applications of RRCA are generally necessary to achieve significant therapeutic effects. While this seems to be generally rather well tolerated, some patients apparently seem to have an increased risk for serious side effects when treated repeatedly with RRCA. 43 The rtTA-tTS-RRCA system may help to reduce this risk, since it allows adenoviral replication to be controlled by the nontoxic inducer drug doxycycline, thereby providing additional safety features for RRCAs.
Both the rtTA-tTS-RRCA and tTS-RRCA systems may be further developed with regard to safety and efficiency in several ways. One way to further restrict the replication of adenoviruses to tumor cells is the insertion of a tumor-specific promoter to drive the E1A gene. 9, 10, [14] [15] [16] 20 Here, we show data delineating kind of an 'inverted' principle: 'tissue protective' gene therapy using the rtTA-hAAT tTS-RRCA system in which liver-specific hAAT-promoter-driven tTS expression inhibits E1A gene expression from the Ad5TRE-E1A. We have shown that the tTS expressed from the hAAT-promoter efficiently protects hAAT-positive HepG2 cells from viro-oncolysis, while hAAT-negative EA.hy926 cells were efficiently lysed. With respect to investigations in vivo, it is important to note that the human hAAT promoter has a very low activity in mouse hepatocytes, 52 and also that replication of human adenoviruses in rodent cells is very inefficient. 26 To show that Ad5TRE-E1 replication can be regulated by the rtTA-hAAT tTS-RRCA system in vivo, too, we therefore analyzed the growth of a subcutaneous human HepG2 tumor xenograft as an indicator of Ad5TRE-E1A replication. The tumor volume was significantly reduced in animals receiving dox with their drinking water as compared to control animals not receiving dox (Figure 9 ). This suggests that tissuespecific expression of tTS was able to suppress Ad5-TRE-E1A replication in vivo, too, in a tissue-specific manner. This principle of 'tissue protective' gene therapy may be particulary useful when metastases grow in an organ composed of relatively few different cell types for which specific promoters are available. For example, it may be possible to achieve protection of the liver against RRCA replication by using a 'hepatocyte-protective' regulatory AdV such as the Ad5 hAAT tTS, while in the metastases the RRCAs are still able to replicate efficiently because of their lack of a 'protective' endogenous promoter.
A possible disadvantage of the rtTA-tTS-RRCA system in its present form is the use of three separate AdVs. While our study was under way, it has been shown that tTS, rtTA, and a response transgene can be co-expressed from a single vector. 53 Studies are under way to examine if it is possible to insert the Tet-On regulators and the E1A-cDNA of the rtTA-tTS-RRCA system into the same AdV genome without acquiring unwanted interactions.
In conclusion, we have developed and evaluated three different dox-controlled RRCA systems (rtTA-RRCA, tTS-RRCA, and rtTA-tTS-RRCA system) based on an E1B/E3-deleted AdV and the Tet-On gene expression system. The rtTA-tTS-RRCA system yielded the best pharmacological control of adenovirus replication and viro-oncolysis, and the best regulation of transgene expression from a cotransduced replication-deficient AdV. Furthermore, it allows incorporation of other safety features such as tissue-and/or tumor-specific promoters and has the potential to be immediately combined with other currently available RRCAs and AdV gene expression systems. The system has considerable potential for the further improvement of the safety of AdV-based gene therapy protocols.
Materials and methods
Plasmid constructs
The rtTA2(s)-M2 was amplified from the plasmid pUHDrtTA2 S -M2 32 using the primers rtTA-XbaIk.o. (5 0 -CCCGAATTCACCATGTCAAGACTGGACAAGAG-3 0 ) and rtTA-BamHI (5 0 -TCATGTCTGGATCCTTACTTAGT TACCC-3 0 ). It was inserted via EcoRI/BamHI restriction sites into the plasmid pZS2 54 resulting in the shuttle plasmid pZS2-CMV-rtTA. The tTS was amplified from the plasmid pTet-tTS (Clontech, Weiterstadt, Germany) using the primers tTS-763s-EcoRI (5 0 -CCCGAATTCAC CATGTCAAGATTAGATAA-3 0 ) and tTS-1623-HindIII (5 0 -CTCAA-GCTTACCAGGGATCCTCTCCTT-3 0 ) and inserted into pZS2 via EcoRI/HindIII restriction sites, Tetracycline-regulatable oncolytic adenovirus H Fechner et al resulting in the shuttle plasmid pZS2-CMV-tTS. For tissue-specific expression of tTS, the CMV promoter/ enhancer of pZS2-CMV-tTS was replaced via NotI/ BamHI restriction sites by the hAAT promoter resulting in the generation of the shuttle plasmid pZS2-hAAT-tTS. hAAT (À357 to +56 bp) 40 was amplified from human genomic DNA isolated from HEK293 cells. For the construction of the shuttle plasmid pAd5TRE-E1A expressing E1A-13S-cDNA, the bovine growth hormone termination signal (bGH-TS) was taken from pZS2 and inserted via HindIII/XbaI restriction sites into pTRE2 (Clontech). The E1A-13S-cDNA was amplified from an RCA present in the Ad5CMVhCARas 54 by PCR using primers E1-560s-BamHI (5 0 -CGGGGATCCAATGAGA CATATTATCT-3 0 ) and E1a-1545a-NheI (5 0 -CGCGCTAG CTTATGGCCTGGGGCGTT-3 0 ). The E1A-13S-intron sequence and an XbaI site were deleted by overlapextension mutagenesis PCR. 55 The resulting fragment was inserted via BamHI/NheI restriction sites upstream of the bGH-TS resulting in the plasmid pTRE-E1A. Alternatively, the E1A-12S-cDNA, generated by deleting the CR3 domain of the E1A-13S-cDNA by overlapextension mutagenesis PCR, was inserted upstream of the bGH-TS, resulting in the plasmid pTRE-12S. The shuttle plasmid pAd5TRE-E1A was produced by insertion of the 5 0 -ITR of adenovirus 5 amplified from pZS2 using the primers E1-1s-XhoI (5 0 -GAGCTCGAGCAT CATCAATAATATACC-3 0 ) and E1a-342-XhoI (5 0 -ACACTCGAGTATTACGCGCTATAGGTAACA-3 0 ) via a singular XhoI restriction site upstream of the TRE of pTRE-E1A. The plasmid pAd5TRE-luc was generated by replacement of the E1A-13S-cDNA in pAd5TRE-E1A by luciferase cDNA. Luciferase cDNA was amplified from the plasmid pTRE-Luc (Clontech). Before insertion, its XbaI site was knocked out by overlap-extension mutagenesis PCR.
Adenovector contructs
The shuttle plasmids pZS2-CMV-rtTA, pZS2-CMV-tTS, pZS2-hAAT-tTS, pAd5TRE-E1A and pAd5TREluc were linearized with XbaI, ligated to the 5' long arm of XbaIdigested E1-E3-adenovirus mutant RR5, transfected into HEK293 cells and propagated as described. 56 The Ad5CMVluc, Ad5CMVrTTP, Ad5CMVGFP and RCA have been described. 54 All adenoviral constructs were tested for RCA contamination by PCR as described. 54 
Cell lines
The following cell lines were used: EA.hy926 is a hybrid cell line from HUVEC and A549. 57 HepG2 is a human hepatocellular carcinoma cell line. HT-29 is a human colorectal carcinoma cell line. MeWo is a human melanoma cell line. Primary human dermal fibroblasts were isolated and cultured as described. 58 All cell lines were grown at 371C in a humified atmosphere containing 5% CO 2 .
Cell killing assays EA.hy926 cells grown in monolayers, MeWo cells grown at a confluence of 80%, or HepG2 cells grown at a confluence of 60% were transduced with 2.5 Â 10 3 p/c Ad5CMVtTS, Ad5 hAAT tTS, and Ad5CMVrtTA or doseequivalent amounts of control AdV Ad5CMVrTTP, respectively, in a medium containing 10% FCS for 24 h. Thereafter, the medium was replaced by fresh medium containing 2% FCS. Cells were reinfected with 5 Â 10 2 p/ c Ad5TRE-E1A, RCA or dose-equivalent amounts of control AdV Ad5CMVrTTP, respectively. E1A-13S gene expression was induced by addition of 1 mg/ml dox daily. CPE was monitored by staining viable cells with crystal violet.
Plasmid transfections
Plasmid transfection was carried out by using a calcium phosphate transfection kit (Stratagene, Heidelberg, Germany). EA.hy926 cells were seeded on six-well plates and transfected with 2 mg plasmid in the presence of medium containing 6% MBS. After 3 h, cells were washed three times with PBS and overlayed with fresh medium containing 10% FCS. Luciferase expression was analyzed 21 h later.
Northern blot analyses
Northern analyses of cellular RNA were performed as described. 59 tTS-, rtTA-, E1A-, hAAT-, and GAPDH-DNA fragments were amplified using cDNA-specific primers. [ 32 P]dCTP labeling of ss-antisense DNA probes and hybridization was carried out as described. 59 The hybridization filters were exposed to Kodak Biomax MS films (Integra Bioscience, Fernwald, Germany).
Detection of adenoviral DNA replication
We used the principle of adenoviral trans-complementation 54 for detecting adenoviral replication. Genomic plus episomal vector DNA were isolated using the E.Z.N.A. Tissue DNA Kit II (Pequlab, Biotechnologie GmbH, Erlangen, Germany). For preparation of the luciferase standard DNA for competitive PCR, mutagenic PCR was performed using overlap-extension mutagenesis as described, 55 resulting in the loss of a 12-base-pair (bp) fragment in the competitive DNA standard. The DNA standard had a total length of 81 bp. For competitive PCR, 50 ng of episomal/AdV DNA mix and luciferase standard DNA were amplified using the primer pair luc334s (5 0 -CCGGCGCCATTCTATCC-3 0 ) and FAM-luc-426a (5 0 -FAM-AGCAATTGTTCCAGGAACCA-3 0 ) for 15 cycles. For internal loading control, episomal/AdV DNA and GAPDH standard DNA were amplified for 23 cycles as described. 54 The fluorescence-labeled amplification products were detected by capillary electrophoresis on an ABI 310 Genetic Analyzer (Applied Biosystems,Weiterstadt, Germany) and the amounts of AdV DNA were calculated as described. 59 
Animal models
To determine the ability of tissue-specific regulation of RRCA replication, HepG2 cells were infected with Ad5 hAAT tTS (2 Â 10 3 p/c) and Ad5CMVrtTA (5 Â 10 2 p/ c) for 24 h and thereafter with Ad5TRE-E1A (2 Â 10 2 p/c) for 3.5 h. In the control group, the cells were infected with Ad5 hAAT tTS and Ad5CMVrtTA only. The cells were harvested and 5 Â 10 6 cells were injected subcutaneously into the flank of athymic nude mice. Four mice were used per group. Doxycycline-HCl (Sigma, Taufkirchen, Germany) was dissolved in drinking water at a final concentration of 200 mg/ml in 5% sucrose and given over the whole investigation period beginning 2 days before the cells were injected. The tumor volume was calculated after the removal of the tumors 9 weeks after injection of 
Luciferase detection
Measurement of luciferase activity was carried out by luminometric assay (Boehringer Mannheim, Germany) as described. 59 
Statistical analysis
Statistical significance of treatments in vivo was analyzed by Student's t-test for normally distributed values.
Activation of the Tet systems
Systems were induced by 300 ng/ml dox daily unless indicated otherwise.
